TNNI3K in cardiovascular disease and prospects for therapy
- 1 May 2015
- journal article
- review article
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 82, 167-173
Abstract
No abstract availableKeywords
Funding Information
- Netherlands Cardiovascular Research Initiative (CVON2012-10)
- Dutch Heart Foundation (2009B66)
This publication has 44 references indexed in Scilit:
- Global Burden of Cardiovascular DiseaseJACC, 2014
- TNNI3K, a Cardiac-Specific Kinase, Promotes Physiological Cardiac Hypertrophy in Transgenic MicePLOS ONE, 2013
- Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunctionJournal of Molecular and Cellular Cardiology, 2013
- Dissection of a Quantitative Trait Locus for PR Interval Duration Identifies Tnni3k as a Novel Modulator of Cardiac ConductionPLOS Genetics, 2012
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Tnni3k Modifies Disease Progression in Murine Models of CardiomyopathyPLOS Genetics, 2009
- Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial diseaseNature Clinical Practice Cardiovascular Medicine, 2006
- Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam studyEuropean Heart Journal, 2006
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Long-Term Trends in the Incidence of and Survival with Heart FailureNew England Journal of Medicine, 2002